Progression of primary myelofibrosis to polycythemia vera
article
OA: gold
CC0
AI-generated summary
This case report details a patient with primary myelofibrosis who progressed to polycythemia vera, identified by new chromosomal abnormalities, but ultimately showed improved quality of life and prognosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
RATIONALE: This case report describes the progression of primary myelofibrosis (PMF) to polycythemia vera (PV), and discuss its potential mechanisms. PATIENT CONCERNS: The patient was admitted because of abdominal discomfort and enlarged spleen for 19 months. DIAGNOSIS: A case of PMF progressed to PV was retrospectively analyzed. There were 19 months between the diagnosis of PMF and PV. The JAK2 V617F mutation was positive before and after the diagnosis of PV; however, new chromosomal abnormalities were detected during the progression. INTERVENTIONS: For treatment of PMF, the danazol, calcitriol, and thalidomide were given. Then, the use of thalidomide and calcitriol was stopped, and hydroxyurea was started. For treatment of PV, interferon treatment was given, whereas hydroxyurea was continued. OUTCOMES: After 30 months of the progression (at the recent follow-up), this patient had no obvious symptoms or thrombosis. LESSONS: PMF rarely progresses to PV, however, the progression will significantly improve the quality of life and prognosis.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (29)
- doi:10.1182/blood-2008-07-170449 via openalex
- doi:10.1002/cncr.21297 via openalex
- doi:10.1016/j.bbmt.2009.10.025 via openalex
- doi:10.1111/j.1365-2141.2007.06741.x via openalex
- W61361573 via openalex
- doi:10.1056/nejmc1109555 via openalex
- doi:10.1038/leu.2010.148 via openalex
- doi:10.1016/j.amjmed.2004.06.032 via openalex
- doi:10.1056/nejme1115119 via openalex
- W2442783759 via openalex
- W6602528013 via openalex
- doi:10.1182/blood-2011-11-395228 via openalex
- doi:10.1182/blood-2013-03-493049 via openalex
- doi:10.1182/blood-2007-04-083501 via openalex
- doi:10.1200/jco.2010.32.2446 via openalex
- doi:10.1182/blood-2007-11-121434 via openalex
- doi:10.1182/blood.v122.21.297.297 via openalex
- doi:10.1002/ajh.24592 via openalex
- doi:10.1111/j.1600-0609.1978.tb01555.x via openalex
- doi:10.1182/blood-2009-09-245837 via openalex
- doi:10.1016/j.mayocp.2011.11.001 via openalex
- doi:10.1182/blood-2013-02-485888 via openalex
- doi:10.1002/ajh.23617 via openalex
- doi:10.1016/s0140-6736(05)67785-9 via openalex
- doi:10.3324/haematol.13346 via openalex
- doi:10.1111/j.1751-553x.2008.01102.x via openalex
- doi:10.1111/j.1600-0609.1983.tb01464.x via openalex
- doi:10.1182/blood-2008-09-178541 via openalex
- doi:10.1111/j.1365-2141.2005.05535.x via openalex
Source provenance
- openalex
- last seen: 2026-05-14T07:19:29.047988+00:00
License: CC0
· commercial use OK